- Business
- Ginwa Enterprise (Group) Inc. Ginwa Enterprise (Group) Inc. engages principally in the research, development, production, and sale of pharmaceuticals in China. The company offers a range of products including orthopedic medicines such as Jintiange capsules; immune products like Jinhua brand transfer factor capsules and transfer factor oral liquid; pediatric, antibiotic, digestive system, gynecological, cardiovascular, antipyretic, analgesic, antiviral, and other therapies; as well as chemical drugs, proprietary Chinese medicines, raw materials, and health-related products in forms including tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions. It operates primarily in the healthcare sector with a focus on biopharmaceuticals, proprietary Chinese medicines, and chemicals, targeting domestic markets through its complete drug R&D, production, and sales system, and also engages in pharmaceutical logistics, hotel services, and rental business. Ginwa Enterprise (Group) Inc. , founded in 1996 and headquartered in Xi'an, Shaanxi Province, China, maintains 588 employees and conducts its operations across China. Recent developments include the completion in 2024 of a share repurchase program involving 20,557,582 shares for CNY 149.49 million; the 100% equity transfer of Jinhua International Hotel Co., Ltd.; cancellation of the board of supervisors and amendments to the articles of association; director resignations and elections including employee representatives; cancellation and re-pledging of controlling shareholder shares; and in November 2025, a controlling shareholder equity transfer agreement involving acting-in-concert parties.